Evidence map›Paper›PMID 35854278›Full record

ArticleBMC public health2022

A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.

Antoinette L Spector, Carol L Galletly, Erika A Christenson, H Danielle Green Montaque, Julia Dickson-Gomez

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Antoinette L SpectorDepartment of Rehabilitation Sciences and Technology, College of Health Sciences, University of Wisconsin-Milwaukee, P.O. Box 413, Milwaukee, WI, 53201, USA. aspector@uwm.edu.ORCID 0000-0002-5821-7881
Carol L GalletlyDepartment of Psychiatry and Behavioral Medicine, Center for AIDS Intervention Research, Medical College of Wisconsin, 2701 N. Summit Ave, Milwaukee, WI, 53202, USA.
Erika A ChristensonCenter of Excellence in Women's Health, Boston, Medical Center/BUSM, 801 Massachusetts Avenue, Boston, MA, 02118, USA.
H Danielle Green MontaqueInstitute for Community Research, 2 Hartford Square West, 146 Wyllys St., Suite 100, Hartford, CT, 06106, USA.
Julia Dickson-GomezDivision of Epidemiology, Institute for Health and Equity, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Medical College of Wisconsin · USBoston Medical Center · USInstitute For Community Research · USUniversity of Wisconsin–Milwaukee · US

Funding

Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV TransmissionR01DA044971 · NIDA · MEDICAL COLLEGE OF WISCONSIN · PI DICKSON-GOMEZ, JULIA B · 2018 to 2022
$3.0M
NIDA NIH HHS R01 DA044971
6 · The paper itself

Abstract

backgroundPrevention of opioid-involved overdose deaths remains a public health priority in the United States. While expanding access to naloxone is a national public health strategy, it is largely implemented at the state and local level, where significant variability in policies, resources, and norms exist. The aims of the current study were to examine the social context of naloxone access in three different states (Connecticut, Kentucky, Wisconsin) from the perspectives of key informants (first responders, harm reduction personnel, and pharmacists), who play some role in dispensing or administering naloxone within their communities.

methodsInterviews were conducted with key informants who were in different local areas (urban, suburban, rural) across Connecticut, Kentucky, and Wisconsin. Interview guides explored the key informants' experiences with administering or dispensing naloxone, and their perspectives on opioid overdose prevention efforts in their areas. Data analysis was conducted using multistage inductive coding and comparative methods to identify dominant themes within the data.

resultsKey informants in each of the three states noted progress toward expanding naloxone access, especially among people who use opioids, but also described inequities. The key role of harm reduction programs in distributing naloxone within their communities was also highlighted by participants, as well as barriers to increasing naloxone access through pharmacies. Although there was general consensus regarding the effectiveness of expanding naloxone access to prevent overdose deaths, the results indicate that communities are still grappling with stigma associated with drug use and a harm reduction approach.

conclusionFindings suggest that public health interventions that target naloxone distribution through harm reduction programs can enhance access within local communities. Strategies that address stigmatizing attitudes toward people who use drugs and harm reduction may also facilitate naloxone expansion efforts, overall, as well as policies that improve the affordability and awareness of naloxone through the pharmacy.

Indexed as

Drug OverdoseOpioid-Related DisordersAnalgesics, OpioidConnecticutHumansKentuckyNaloxoneNarcotic AntagonistsUnited StatesWisconsinAnalgesics, OpioidNaloxoneNarcotic AntagonistsAccessNaloxoneNarcan®Opioid overdose preventionQualitative research

Identifiers

PMID35854278
PMCPMC9295344
OpenAlexW4285795671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.